Shares of the drug's maker, biotech AtheroGenics of Atlanta, shed 60% of their value in premarket trading after the test results were announced.

FORBES: Magazine Article

Shares of the drug's maker, biotech AtheroGenics (nasdaq: AGIX - news - people ) of Atlanta, shed 60% of their value in premarket trading after the test results were announced.

FORBES: Strange Days For AtheroGenics